Multicentric Phase III Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Metastatic Breast Cancer in First-line Treatment
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 280
- 试验地点
- 19
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
The previous reported phase I study allows us to prospectively define the optimal total dose in different metastatic locations (88). However, several questions are still unanswered such as the adequate timing of the stereotactic body radiation therapy (SBRT) in oligometastatic disease. Indeed, there are two different oligometastatic states: "de novo", i.e. occurring at first metastatic presentation without any previous systemic therapy; and "secondary", defined as residual disease after systemic treatment.
The investigators wish to prospectively study the role of metastases SBRT with curative intent in de novo oligometastatic disease.
This clinical trial would be the first randomized study studying SBRT at onset of the metastatic disease. If this trial shows a PFS improvement, it will definitively change the standard of treatment and it will highlight SBRT as a key treatment of metastatic disease. It will confirm the oligometastasis hypothesis as well as the Simon Norton hypothesis (92).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven breast cancer stage IV AJCC TNM
- •Age >18 years
- •WHO status</=2
- •Hormonal receptors positive breast cancer (IHC)
- •The primary tumor was treated or will be treated with curative intent (surgery and /or radiotherapy)
- •No prior treatment for metastatic relapse. It will be accepted patients which would have begun a treatment in the case where:
- •Hormonotherapy </= 1 month
- •Chemotherapy </= 1 cycle
- •The treatment must be stopped after signature of the consent form.
- •a. Metastatic lesions out of previous radiation field;
- •b. Equal or less than 5 metastatic lesions (measurable or not);
- •c. In case of measurable lesions, each </=10 cm or </=500 mL
- •For liver mets:
- •adequate liver function (liver enzyme <3N, bilirubin <30mg/dl, albumin >2.5g/dl)
- •no underlying cirrhosis or hepatitis
- •liver metastase size </=7cm diameter
- •not adjacent to stomach or small bowel
- •For abdominal mets:
- •a. adequate renal function with a creatinine clearance (Cockroft formula) > 60ml/min
- •Absence of any psychological, familial, sociological or geographical condition with a potential to hamper compliance with the study protocol and follow-up schedule
- •Life expectancy > 3 months
- •Affiliated to Health Insurance regimen
- •Written and signed consent form
- •Non-inclusion Criteria:
- •Triple negative breast cancer
- •Prior systemic treatment in metastatic setting (endocrine therapy, chemotherapy, targeted therapies, radionuclide)
- •Brain metastases
- •In spinal cord mets:
- •More than 3 consecutive and contiguous spinal segments involved by tumor
- •Neurological examination prior randomization > 1 week
- •Inability to tolerate treatment (unable to lie flat)
- •Treated with radionuclide/systemic chemotherapy within 30 days before SBRT
- •Significant or progressive neurological deficit
- •More than 25% spinal canal compromise
- •Malignant epidural spinal cord compression or cauda equina syndrome
- •Spine instability or neurological deficit resulting from bony compression of neural structures
- •Scleroderma or connective tissue disease as a contraindication to radiotherapy
- •Pregnancy or breast feeding period
排除标准
- 未提供
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: evaluated with a minimal follow-up of 3 years in all patients
events: local recurrence, distant progression of the target metastases, any new metastasis, death of any cause The definition of progression is based on RECIST1.1 criteria. Progression is assessed locally, in any metastasis present at the time of randomization or in any newly diagnosed metastasis.
次要结局
- Cumulative rate of local failure(evaluated with a minimum follow-up of 3 years in all patients.)
- Overall survival(evaluated with a minimum follow-up of 3 years in all patients)